Avient proudly accepted the challenge to support the design and development of a diagnostic device that could easily and efficiently determine the eyeglass prescriptions for many under-resourced communities. The USee™ device will be part of the permanent collection at The Henry Ford Museum of American Innovation (Dearborn, Mich.), an IDSA partner. This award is proof that the USee™ device not only graduated but was the valedictorian.

Power Management Mobile Devices IVD Devices

SBD cordless power tool GLOBAL CLOUD SERVICE PROVIDER I N T E R N A L H O L D O F S E R V E R C A B I N E T S • PC-based solution with good impact strength • UL 94 V-0 certification • Dimensionally stable • Offered a 40% glass fiber-reinforced PC solution with high modulus and high impact strength • Achieved a UL 94 V-0 flammability rating at 3.0 mm • Provided pre-colored formulation that met specific white requirements and maintained good color stability even after long-term production at high temperatures • Ensured high flowability so the material could be injected with low pressure, avoiding damage to the metal frame Edgetek Engineered Polymer Formulations KEY REQUIREMENTS WHY AVIENT?

Engage in the development and use of climate friendly products and processes to reduce power consumption and greenhouse gas emissions

Engage in the development and use of climate friendly products and processes to reduce power consumption and greenhouse gas emissions

UV BLUE DEVICE 7386C UV YELLOW DEVICE 101C UV ORANGE DEVICE 144C

Mevopur™ Healthcare Colorants and Formulations and Mevopur™ Healthcare Functional Additives for In Vitro Diagnostic Devices Diagnostic devices and consumables, now more than ever, play a vital role in delivery of safe treatements. New innovations in diagnostic equipment such as improvement in laboratory automation and self-testing devices/POCT (Point-of-Care Testing) diagnostics require increased reliability. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.

Sustainable infrastructure solutions that increase energy efficiency, renewable energy, natural resource conservation and fiber optic / 5G network accessibility Below is a reconciliation of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP. Below is a reconciliation of these non-GAAPfinancial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP.

Other highlighted polymer solutions for manufacturers of drug delivery devices, in vitro diagnostic equipment, and pharmaceutical packaging at the show include: Functional additives — to enhance the performance and reliability of drug delivery devices and in vitro diagnostics by promoting low retention, low friction, conductivity, sterilization stability, ultraviolet (UV) stability, solvent-free laser marking, and more Pharmapack 2025, Europe’s leading packaging and drug delivery device event, will take place January 22–23 at the Paris Expo, Porte de Versailles.

The ability to successfully integrate acquired companies into our operations, retain the management teams of acquired companies, retain relationships with customers of acquired companies, and achieve the expected results of such acquisitions, including whether such businesses will be accretive to our earnings; • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Changes in polymer consumption growth rates and laws and regulations regarding the disposal of plastic in jurisdictions where we conduct business; • Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; • Fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • Information systems failures and cyber attacks; and • Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. Below is a reconciliation of these non-GAAP financial measures to their most directly comparable financial measures calculated and presented in accordance with GAAP. Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016 2017 Net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 Joint venture equity earnings, after tax (19.0) (14.7) (3.7) — — — — — — Special items, before tax(1) (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 Special items, tax adjustments(1) (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation